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Abstract
Background: During pregnancy, many patients with rheumatoid arthritis (RA) experience disease improvement,
whereas patients with ankylosing spondylitis often suffer from persistent active disease. Here we investigated
whether pregnancy-related changes in disease activity were associated with changes in the proportion and
function of γδT cells.
Methods: The study population comprised 55 patients with RA, 31 patients with ankylosing spondylitis, and 35
healthy controls. Among these participants, 28 RA patients, 21 ankylosing spondylitis patients, and 23 healthy
controls were investigated once before conception when possible, at each trimester of pregnancy, and at 8 weeks
postpartum. Data were compared with age-matched non-pregnant patients to obtain disease-related background.
In all subjects, peripheral Vδ1 and Vδ2 T cells were analyzed for cell frequencies, the activation marker CD69, the
cytotoxicity markers NKG2D and NKG2A, and the intracellular cytokines tumor necrosis factor (TNF)α, interferon
(IFN)γ, interleukin (IL)-17 and IL-10.
Results: Pregnant patients showed a decreased Vδ2/Vδ1 ratio in the third trimester, which resulted from a slightly
reduced proportion of Vδ2 cells. Changes in RA disease activity during pregnancy and postpartum were not
associated with numerical proportions of γδT cells but with changes of the cell activation marker CD69 on Vδ1 and
Vδ2 cells. Only RA patients showed reduced proportions of TNFα-positive Vδ1and Vδ2 cells and IFNγ-positive Vδ2
cells at the third trimester of pregnancy, a finding that was not apparent in the entire population of CD3 T cells.
The proportions of IL-17-positive γδT cells and IL-10-positive γδT cells did not differ between pregnant and non-
pregnant women of the different groups.
Conclusions: Changes of disease activity in pregnant RA patients were associated with functional changes in both
γδT cell subsets. This reduced pro-inflammatory profile of γδT cells might contribute to the immunomodulation
resulting in pregnancy-induced improvement of RA.
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Background
Successful pregnancy requires an extraordinary state of
natural immunomodulation to permit tolerance towards
the haploidentical fetus [1]. The maternal immune system
is altered to allow tolerance of fetal antigens while still
being able to fight against infections. These immunomod-
ulatory effects of pregnancy have varying influences on
autoimmune rheumatic diseases. Rheumatoid arthritis
(RA) improves in the majority of patients, whereas anky-
losing spondylitis (AS) often remains active or is aggra-
vated [2]. The understanding of relevant factors involved
in the pregnancy-induced improvement of RA may en-
large our understanding of pathogenic factors involved
in RA.
In this context, γδT cells are of interest since they dis-
play immunoregulatory features during pregnancy [3].
These cells are unconventional CD3+ T cells that show
features of both the innate and the adaptive immune
system [4]. In contrast to αβT cells (e.g., CD4 or CD8 T
cells), γδT cells recognize non-peptide antigens inde-
pendently of classical major histocompatibility complex
(MHC) molecules [4]. γδT cells exert their main func-
tions through cytokine release, cytotoxicity, or antigen
presentation [4]. In the peripheral blood of healthy
humans, about 5 % of lymphocytes express γδT cell re-
ceptors [5]. Two main subsets of γδT cells bear different
variable delta (Vδ) chains, Vδ1 and Vδ2, and show dis-
tinct tissue distributions and functions.
At the fetomaternal interface, γδT cells recognize fetus-
derived trophoblast cells that do not express polymorphic
classical MHC class I molecules [6]. The pregnant uterus
shows an increased number of γδT cells [7]. Vδ1 T cells
are the predominant subset in the decidua, where they
produce interleukin (IL)-10 and transforming growth fac-
tor beta [8], while Vδ2 T cells predominate in the periph-
eral blood of healthy pregnant women [9, 10].
In autoimmune diseases, γδT cells have shown both
pro- and anti-inflammatory responses. In the collagen-
induced arthritis mouse model of RA, γδT cells function
differently at different disease stages, playing a pro-
inflammatory role at arthritis onset and an anti-
inflammatory role once the disease is established [11].
Only very limited knowledge is available about γδT cells
in RA or AS in humans. One study reported reduced Vδ2
T cells in the peripheral blood of RA patients compared to
that of healthy controls [12]. Both Vδ1 and Vδ2 have been
found in the synovium of RA patients with a predomin-
ance of interferon (IFN)γ-producing Vδ1 cells [13, 14].
It is currently unknown whether γδT cells play an immu-
noregulatory role in pregnancy-related amelioration of RA.
We hypothesized that pregnancy has a systemic tolerance-
inducing effect that would shift the functional plasticity of
circulating γδT cells towards an anti-inflammatory profile,
potentially impacting disease activity in RA. This shift
would not be observed in a disease that remains active dur-
ing pregnancy, such as AS. In the present study, we investi-
gated phenotypical, and cytokine changes of circulating
γδT cells during pregnancy in patients with RA as com-
pared to those with AS and healthy controls.
Methods
Patients
Here we prospectively studied 72 pregnant women: 28
with RA, 21 with AS, and 23 healthy controls. Pregnant
individuals were examined once before conception when
possible (up to 6 months before conception), once at each
trimester (during gestational weeks 10–12, 20–22, and
30–32), and once at 8 weeks postpartum. Additionally, we
studied 49 non-pregnant age-matched individuals, includ-
ing 27 women with RA, 10 with AS, and 12 healthy
women. Table 1 shows the patient characteristics and
medications. All patients gave written informed consent,
and the study was approved by the ethical committee of
the Canton of Bern.
All patients were recruited from the pregnancy clinic
of the Department of Rheumatology, Immunology, and
Allergology and the Department of Obstetrics and
Gynecology at the Inselspital of Bern, Switzerland. RA
patients fulfilled the American College of Rheumatology
criteria [15]. AS patients all had established axial in-
volvement and fulfilled the modified New York Criteria
[16]. RA disease activity was measured using the Disease
Activity Score 28–C-reactive protein (DAS28-CRP) with
three variables: swollen joint count, tender joint count,
and C-reactive protein (CRP). AS disease activity was
measured using the Ankylosing Spondylitis Disease
Activity Score–C-reactive Protein (ASDAS-CRP). Serum
CRP was measured either by Nycocard CRP Single
Assay (Alere GmbH, Wädenswill, Switzerland) or high-
sensitivity CRP test (Department of Clinical Chemistry,
Inselspital, University of Bern, Switzerland). The healthy
control individuals included in the study each had a CRP
below 5 mg/L. Patients and healthy women with infec-
tions were excluded from the study.
Cell preparation and flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized blood by standard density-gradient
centrifugation over Biocoll (Biochrom AG, Berlin,
Germany). For the frequency analysis of CD3, Vδ1 and
Vδ2, and for the analysis of the activation marker and the
cytotoxicity marker, the following directly labeled monoclo-
nal antibodies were used: the PerCP-conjugated antibody
CD3 (clone SK7) from Biolegend, the fluorescein-
isothiocyanate-conjugated antibodies Vδ1 (clone TS-1) and
Vδ2 (clone B6) from Thermo Scientific (Waltham, MA,
USA), the phycoerythrin-coupled antibodies CD69 (clone
FN50, Biolegend, San Diego, CA, USA), NKG2A (clone
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Z199, Beckman Coulter, Brea, CA, USA), and the
allophycocyanin-coupled antibodies NKG2D (clone 1D11).
Immunofluorescence staining was performed after washing
the cells twice with phosphate-buffered saline containing
1 % human serum. Cells were incubated for 20 minutes
with each monoclonal antibody.
For the intracellular cytokine staining, cells were plated in
48-well plates at 1 × 106 cells/100 μL in complete RPMI 1640
containing 1× non-essential amino acids, 1× glutamine, 1×
sodium pyruvate, 1× kanamycin (Life Technologies, Carlsbad,
CA, USA), and 5 % pooled human serum (Blood Transfusion
Service, Bern, Switzerland) and stimulated with phorbol myr-
istate acetate (PMA; 25 ng/mL; Sigma Aldrich, St. Louis,
MO, USA) and ionomycin (1 μg/mL; Sigma Aldrich) for
4 hours in the presence of the protein transport inhibitor
Brefeldin A (10 μg/mL; Sigma Aldrich). Intracellular cytokine
staining was performed with the following antibodies:
phycoerythrin-coupled antibodies, tumor necrosis factor
(TNF)α (clone MAb11) and IL-10 (clone JES3-19 F1) from
BD Biosciences (San Jose, CA, USA), and allophycocyanin-
coupled antibodies, IFNγ (clone B27) from Biolegend and
IL-17A (clone eBIO64DEC17) from eBioscience (San Diego,
CA, USA). After surface and intracellular staining of PBMCs,
data acquisition was performed using FACSCalibur 4-Color
Cytometer (BD Biosciences), and data were analyzed using
FlowJo Software (FlowJo, Ashland, OR, USA). Intracellular
cytokine data were studied using both the proportion of
cytokine-positive cells and the geometric mean fluorescence
intensity (MFI) of a gated cell population.
Statistical analysis
All data are reported as the median and range. The
Mann-Whitney U test was used for unpaired data analysis
and group-wise comparison. The Wilcoxon signed-rank
test was applied for longitudinal comparisons of paired
samples. Linear regression analysis was used to investigate
the association between disease activity and γδT cell fea-
tures. Data were analyzed using IBM SPSS Statistics 21
software. A P-value below 0.05 was considered significant.
Results
Disease activity improved in pregnant RA patients
A total of 49 pregnant patients and 23 healthy pregnant
women were examined before (when possible), during
Table 1 Patient characteristics
Healthy
control
Rheumatoid
arthritis
Ankylosing
spondylitis
Total number
Total 35 55 31
Non-pregnant 12 27 10
Pregnant 23 28 21
Age in years; median (range)
Non-pregnant 30.5 (24–48) 32.5 (17–51) 35 (30–47)
Pregnant 33 (23–41) 32 (28–39) 32.5 (27–39)
Rheumatoid factor positive
Non-pregnant 19 (59.4)
Pregnant 13 (46.4)
ACPA positive
Non-pregnant 17 (53.1)
Pregnant 12 (42.9)
HLA-B27 positive
Non-pregnant 7 (70)
Pregnant 14 (66.7)
Medication
NSAID
Non-pregnant – 25 (75.8) 7 (70)
3rd trimester – 4 (14.3) 5 (23.8)
Postpartum* – 7 (25) 9 (42.9)
Prednisone**
Non-pregnant – 12 (36.4) 1 (10)
3rd trimester – 13 (46.4) 3 (14.3)
Postpartum* – 9 (32.1) 2 (9.5)
Sulfasalazine
Non-pregnant – 8 (24.2) 1 (10)
3rd trimester – 5 (17.9) –
Postpartum* – 7 (25) 1 (4.8)
Antimalarials
Non-pregnant – 1 (3) –
3rd trimester – 2 (7.1) –
Postpartum* – 5 (17.9) –
Methotrexate
Non-pregnant – 7 (21.2) –
3rd trimester – – –
Postpartum* – – –
Leflunomide
Non-pregnant – 1 (3) –
3rd trimester – – –
Postpartum* – – –
Table 1 Patient characteristics (Continued)
TNF inhibitors
Non-pregnant – 5 (15.2) 3 (30)
3rd trimester – – –
Postpartum* – 2 (9.5)
All values are shown as n (%) except where indicated otherwise. *Postpartum:
6–8 weeks after birth; ** < 15 mg/day. ACPA anti citrullinated peptide antibodies,
NSAID Non-steroidal anti-inflammatory drug (until gestation week 32), TNF Tumor
necrosis factor
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and after pregnancy (Table 1). In RA patients, the dis-
ease activity scores according to DAS28-CRP were lower
at the third trimester than 8 weeks postpartum (P = 0.03;
Fig. 1a). Though less medication was used by the preg-
nant patients than by the non-pregnant control group,
inactive disease was commonly seen in pregnant RA pa-
tients, with 58–69 % of RA patients showing low disease
activity (DAS28-CRP scores <3.2; Fig. 1b). In contrast,
disease activity in AS patients as measured by ASDAS-
CRP remained unchanged during and after pregnancy
(Fig. 1c). During pregnancy, 57–80 % of AS patients expe-
rienced active disease (ASDAS-CRP scores >2.1; Fig. 1d).
Discrete quantitative changes of Vδ1 and Vδ2 cells in
pregnant patients
With regard to the percentages of Vδ1 and Vδ2 T cells
within the CD3+ population, we first investigated the dif-
ferences during and after pregnancy as well as the differ-
ences between pregnant and non-pregnant controls.
Because of the lack of sufficient pre-pregnancy data in
healthy women and AS patients, pre-pregnancy data
were excluded from the analysis. In healthy subjects, the
postpartum proportion of Vδ1 T cells was higher com-
pared to that of the third trimester (P = 0.02) and higher
compared to that of non-pregnant controls (P = 0.04;
Fig. 2a). Concerning Vδ2 cells of longitudinally followed
healthy subjects, their frequency did not change. The
proportion of Vδ1 cells and Vδ2 cells in pregnant
healthy women was comparable to that of non-pregnant
healthy women (Fig. 2a and b).
Among pregnant RA patients, Vδ1 T cell frequencies
did not show significant changes during pregnancy. In
contrast, Vδ2 T cells significantly decreased from the first
trimester to the third trimester (P = 0.02), as well as from
the second trimester to the third trimester (P = 0.02;
Fig. 2b). To detect small changes in the balance between
Vδ2 and Vδ1 cells, we calculated the Vδ2/Vδ1 ratio
(Fig. 2c). In both pregnant RA patients and pregnant AS
patients, the Vδ2/Vδ1 ratio decreased from the first tri-
mester to the third trimester (RA, P = 0.01; AS, P = 0.03).
Among pregnant AS patients, the Vδ2/Vδ1 ratio was
lower at the third trimester than at the postpartum exam-
ination (P = 0.04). These changes in the Vδ2/Vδ1 ratio
could not be observed in healthy controls.
Overall, only discrete quantitative changes of Vδ1 and
Vδ2 T cells were observed during pregnancy, which were
more pronounced in cases of RA than in AS. Interest-
ingly, Vδ2 T cells decreased during pregnancy in cases of
RA when disease activity was very low. In contrast, non-
pregnant RA patients with active disease (DAS28-CRP
a b
c d
Fig. 1 Disease activity before, during and after pregnancy. a Disease activity measured by the Disease Activity Score in 28 joints and C-reactive
protein (DAS28-CRP) for 28 longitudinally followed pregnant rheumatoid arthritis (RA) patients and for 27 non-pregnant RA patients. b The graph
shows the percentages of the abovementioned patients grouped according to DAS28-CRP scores into: remission (DAS28-CRP <2.6), low disease activity
(DAS 28-CRP 2.6–3.2), moderate disease activity (DAS28-CRP >3.2–5.1) and high disease activity (DAS28-CRP >5.1). c Disease activity measured by the
Ankylosing Spondylitis Disease Activity Score and C-reactive protein (ASDAS-CRP) for 21 longitudinally followed pregnant ankylosing spondylitis (AS)
patients and for 10 non-pregnant (np) AS patients. d The graph shows the percentages of patients grouped according to ASDAS-CRP scores into:
inactive disease (ASDAS <1.3), moderate disease activity (ASDAS 1.3– < 2.1), high disease activity (ASDAS 2.1–3.5) and very high disease activity (ASDAS
>3.5). Pregnant patients were analyzed once before pregnancy (pre), at each trimester (1T, 2T, 3T) and 8 weeks postpartum (pp). Boxplots show the
median and the interquartile ranges. *P< 0.05
Tham et al. Arthritis Research & Therapy  (2016) 18:26 Page 4 of 10
>3.2) showed a lower frequency of Vδ2 T cells (median
0.80, range 0.16–3.48) compared to non-pregnant RA
patients with the inactive disease (median 2.04, range
0.24–9.54; P = 0.04; data not shown).
Association between disease activity and activation
marker expressed by γδT cells of RA patients
To investigate whether pregnancy-related changes of
disease activity were reflected by changes of cell activa-
tion, we analysed the expression of the activation marker
CD69 on Vδ1 and Vδ2 T cells. The proportion of CD69-
positive Vδ1 and Vδ2 cells did not differ between non-
pregnant healthy women and those at the third trimester
or postpartum time point (Fig. 3a and b). By contrast,
RA patients analyzed 8 weeks postpartum showed higher
percentages of CD69-positive Vδ1 cells than non-
pregnant controls (P = 0.01; Fig. 3a). In AS patients, the
proportions of CD69-positive Vδ2 were highest at the
third trimester and differed from those of non-pregnant
AS patients (P = 0.02) and from those of postpartum AS
patients (P = 0.04).The relationship between disease ac-
tivity and cell activation of γδT cells was then analysed
by linear regression analysis in non-pregnant, pregnant
(third trimester) and postpartum patients. In RA
patients, disease activity as measured by DAS28-CRP
correlated with the proportion of CD69-expressing Vδ1
and Vδ2 cells (Fig. 3c). In AS patients, the association of
CD69-bearing Vδ2 cells and disease activity measured
by ASDAS-CRP showed a slight tendency towards statis-
tical significance (P = 0.08; Fig. 3d). There was no signifi-
cant association between CD69-bearing Vδ1 cells and
ASDAS-CRP.
Increased expression of anti-cytotoxic markers on γδT
cells of pregnant RA patients
The cytotoxic response of γδT cells is modulated by the
activating natural killer (NK) cell receptor NKG2D and
by the inhibiting NK cell receptor NKG2A. We profiled
γδT cells for NKG2A and NKG2D expressions to inves-
tigate whether pregnancy changed the balance between
these functionally different receptors. The proportions of
NKG2D-expressing Vδ1 and Vδ2 cells did not change
from the first trimester until the postpartum time-point
in any group (data not shown). Similar results were seen
when analyzing the MFI of NKG2D among the popula-
tion of Vδ1 and Vδ2 cells.
Pregnant RA patients only displayed a longitudinal
change of NKG2A-positive Vδ1 T cells, with an approxi-
mately 2.4-fold higher proportion at the second trimester
than at the postpartum time-point (median percentage of
NKG2A-positive cells: second trimester, 7.53; postpartum,
3.04; P = 0.02; data not shown). This difference was not
Fig. 2 Longitudinal changes of Vδ1 and Vδ2 T cells during and after pregnancy. The proportions of Vδ1 (a) and Vδ2 cells (b) and the Vδ2/Vδ1 ratio
(c) are shown for healthy controls (left panels), patients with RA (middle panels) and patients with AS (right panels). Pregnant individuals were studied
before pregnancy (pre), at each trimester (1T, 2T, 3T) and postpartum (pp). Values were compared with age-matched non-pregnant (np) individuals in
each group. Frequencies of Vδ1 and Vδ2 T cells are shown as percentages of CD3-positive T cells in isolated PBMCs. Boxplots show the median and
the interquartile ranges. + no data available. *P < 0.05
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seen when analyzing the MFI of NKG2A among the popu-
lation of Vδ1 cells. The proportion of NKG2A-expressing
Vδ2 cells was stable during and after pregnancy in all
groups.
Reduced TNFα and IFNγ production by γδT cells in
pregnant RA patients
To determine the intracellular cytokine profile of γδT
cells, freshly isolated PBMCs were activated with PMA
and ionomycin in the presence of a Golgi transport in-
hibitor and stained for TNFα, IFNγ, IL-17 and IL-10.
We first analyzed longitudinal changes of cytokine-
positive Vδ1 and Vδ2 cells in healthy women and pa-
tients. In RA patients, the population of TNFα-producing
Vδ1 cells decreased from the second to the third trimester
and increased from the third trimester to the postpartum
time point (second to third trimester analyzed by percent-
age of positive cells and by MFI: P = 0.04; third trimester
to postpartum analyzed by MFI: P = 0.04; Additional file 1:
Figure S1).
We then compared differences between pregnant and
non-pregnant individuals. For pregnant individuals, the
third trimester was chosen since this time point was re-
lated to clinical changes of disease activity and
d
Fig. 3 Activation markers expressed by γδT cells and disease activity. Analysis for the proportion of CD69-expressing Vδ1 cells (a) and Vδ2 cells
(b) cells among healthy controls (left panels), patients with RA (middle panels) and patients with AS (right panels). Percentages of CD69-positive
cells are compared between non-pregnant (np) age-matched women and women studied at the third trimester (3T) and postpartum (pp). Data
were analyzed for correlation between CD69-expressing Vδ1 cells (c) and Vδ2 cells (d) and the disease activity scores in pregnant (third trimester),
postpartum and non-pregnant patients with RA (left panels) and AS (right panels). Disease activity in RA patients was measured using Disease
Activity Score in 28 joints and C-reactive peptide (DAS28-CRP) (a) and in AS patients using Ankylosing Spondylitis Disease Activity Score and
C-reactive peptide (ASDAS-CRP) (b)
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quantitative changes of γδT cells. Regarding TNFα pro-
duction, the most pronounced difference appeared be-
tween pregnant and non-pregnant RA patients (Fig. 4a
and b). Pregnant RA patients showed a lower proportion
of TNFα-positive Vδ1 cells compared to non-pregnant
RA patients (P = 0.04). Similarly, pregnant RA patients
showed an approximately 5.7-fold lower proportion of
TNFα-positive Vδ2 cells compared to non-pregnant RA
patients (P = 0.001). With respect to IFNγ (Fig. 4c), non-
pregnant RA patients displayed the highest proportions
e
Fig. 4 Reduced pro-inflammatory cytokine profile of γδT cells in pregnant versus non-pregnant rheumatoid arthritis patients. PBMCs from healthy women
(HC), patients with rheumatoid arthritis (RA), and patients with ankylosing spondylitis (AS) were stained for intracellular cytokines. a Representative
fluorescence-activated cell sorter analysis plots showing the gating strategy of tumor necrosis factor alpha (TNFα)-positive Vδ1 cells and TNFα-positive Vδ2
cells in a non-pregnant and a pregnant RA patient. b–e Percentages of CD3 cells, Vδ1 and Vδ2 cells from non-pregnant women (np, white boxes) were
compared to cells from pregnant women (third trimester; 3T, grey boxes) with regard to intracellular production of TNFα (b), interferon gamma (IFNγ) (c),
interleukin (IL)-17 (d) and IL-10 (e). *P< 0.05, **P< 0.01, ***P< 0.001
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of IFNγ-positive Vδ1 and IFNγ-positive Vδ2 cells, which
significantly differed from the median proportions
found in non-pregnant healthy controls (Vδ1, P = 0.04;
Vδ2, P = 0.02). Analogous to the TNFα results, the pro-
portion of IFNγ-positive Vδ2 cells was lower in preg-
nant RA patients compared to non-pregnant RA
patients (P = 0.03; Fig. 4c). Similar results were found
when analyzing the MFI of TNFα and IFNγ among
the population of Vδ1 and Vδ2 cells (Additional file
2: Figure S2). Interestingly, the reduced percentages
of TNFα- and IFNγ-positive γδT cells observed in
pregnant RA patients were not apparent in the en-
tire population of CD3 T cells (Fig. 4b and c, left
panels).
With respect to IL-17, we found no significant differ-
ence in the proportion of IL-17-positive Vδ1 or Vδ2 cells
between pregnant and non-pregnant women (Fig. 4d).
The median proportions of IL-17-positive Vδ1 and Vδ2
cells were below 4 %. Regarding IL-10, IL-10-positive
cells tended to be lower in pregnant than in non-
pregnant individuals for Vδ1 and Vδ2 T cells, an effect
which was more pronounced for the population of CD3
cells (Fig. 4e). There was no influence of medication on
the proportion of cytokine-positive Vδ1 or Vδ2 cells in
non-pregnant patients.
Overall, among all analyzed individuals, only pregnant
RA patients showed a reduced production of pro-
inflammatory cytokines by Vδ1 and Vδ2 cells.
Discussion
Pregnancy has a positive effect on RA, but has no bene-
ficial effect on AS. In the present study, we analyzed
whether pregnancy-related improvements of RA symp-
toms were associated with changes of circulating γδT
cells. γδT cells are an immune system component that
bridge the innate and the adaptive immune response,
and they show a functional plasticity ranging from im-
munoregulatory properties to pro-inflammatory re-
sponses. We hypothesized that pregnancy has not only a
local- but also a systemic tolerance-inducing effect on
immunoregulatory cells such as γδT cells, which might
support pregnancy-induced amelioration of RA.
Overall, our results demonstrate a reduced pro-
inflammatory cytokine profile of γδ T cells in pregnant
patients with RA compared to non-pregnant RA pa-
tients. This functional modification of γδT cells occurred
in pregnant RA patients of whom 69 % had low disease
activity but not in patients with AS, a disease with on-
going disease activity.
Among the two subsets of circulating γδT cells,
changes were detected in both the Vδ1 and the Vδ2
cells. Against our expectation based on previous findings
on Vδ1 and Vδ2 cells, we did not find an increase in cir-
culating Vδ1 cells during pregnancy that provide a Th2
cytokine pattern as shown for decidual Vδ1 cells [8, 10].
This discrepancy may be explained by the analysis of
peripheral Vδ1 and Vδ2 cells and the use of different
sampling periods. Among pregnant patients with RA
and AS, we identified reduced Vδ2/Vδ1 ratios during
the third trimester of pregnancy, which were due to a
slight pregnancy-related reduction of Vδ2 cells. How-
ever, a previous study also reported reduced Vδ2 cell
percentages among non-pregnant RA patients, a finding
that was not related to disease activity assessed by CRP
and erythrocyte sedimentation rate [17]. By contrast, our
cohort of non-pregnant RA patients showed a lower fre-
quency of Vδ2 T cells in cases with active disease
(DAS28-CRP >3.2) compared to cases with inactive dis-
ease (DAS28-CRP <3.2). Similarly, patients with juvenile
idiopathic arthritis (JIA) suffering from more active dis-
ease showed lower percentages of synovial Vδ1 and Vδ2
T cells [18]. Therefore, we suppose that Vδ2 T cell fre-
quency variations can be triggered by pregnancy and by
disease activity in RA.
However, these quantitative changes may be less import-
ant than functional changes of γδT cells in terms of
reflecting disease activity. In our cohort of pregnant and
non-pregnant RA patients, disease activity was associated
with Vδ1 and Vδ2 T cells that were positive for the activa-
tion marker CD69. Similarly, high CD69 expression on
Vδ2 cells has been reported in inflamed joints of JIA pa-
tients [19]. However, in our RA patients, disease activity
correlated with CD69 positivity on both Vδ1 and Vδ2
cells, which do not respond to the same antigen. Thus, the
increased percentage of CD69-positive Vδ1 and Vδ2 cells
might be induced by a disease-related inflammatory envir-
onment rather than by specific antigens.
γδT cells exert their effector function via both cytokine
release and cytotoxicity. Cytotoxic potency has been de-
scribed for both Vδ1 and Vδ2 cells [20, 21], along with
modulation by the activating NK cell receptor NKG2D
or the inhibiting NK cell receptor NKG2A. The placenta
secretes NKG2D ligands, which could downregulate
NKG2D [22]. Therefore, we expected to find a
pregnancy-induced change of the balance between the
NKG2D and NKG2A expressions on Vδ1 and Vδ2 cells.
However, our results showed that the percentages of
NKG2D-expressing Vδ1 and Vδ2 cells remained un-
changed during pregnancy and postpartum. In contrast,
the percentage of NKG2A-expressing Vδ1 cells was higher
during the second trimester than postpartum in RA pa-
tients. A previous report demonstrated a pregnancy-
related increase of NKG2A-positive γδT cells in healthy
women analyzed around gestational week 27 compared to
non-pregnant controls [10]. The increased expression of
NKG2A on γδT cells might therefore be a pregnancy-
related phenomenon. In this respect, one might speculate
that trophoblast-derived HLA-E binds to the increased
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proportion of NKG2A-positive γδT cells, thereby down-
modulating their cytotoxic potential [23, 24].
Given that γδT cells can produce the pro-inflammatory
cytokines TNFα and IFNγ, which are involved in the
pathogenesis of RA and spondyloarthritis [25, 26], it is
possible that pregnancy induces some dampening of the
TNFα- or IFNγ-producing Vδ1 and Vδ2 cells. This specu-
lation was indeed supported by results in RA patients, but
not in AS patients or in healthy controls. Therefore, an ef-
fect of pregnancy alone, which would appear in all groups,
seems unlikely. However, the local cytokine environment
has a decisive role in driving γδT cell function in a way that
normal pregnancy gives rise to γδT cells with an anti-
inflammatory profile whereas pre-eclampsia gives rise to
γδT cells with a pro-inflammatory profile [27, 28]. The
anti-inflammatory cytokine milieu created by gestational
γδT cells in turn promotes feto–maternal tolerance [28].
Thus, the downregulation of TNFα- and IFNγ-positive γδT
cells in pregnant versus non-pregnant RA patients could
result from a reduced inflammatory milieu that in turn sup-
ports disease improvement.
Disease activity in AS remained unchanged during preg-
nancy. Accordingly, there was no change of TNFα- and
IFNγ-positive γδT cells in pregnant versus non-pregnant
AS patients. Previous research in AS has shown that a
γδT cell subpopulation bearing the IL-23 receptor is the
main source of IL-17-secreting T cells [29]. Our analysis
showed similar percentages of IL-17-secreting γδT cells,
with no differences between the study groups or between
pregnant and non-pregnant individuals. Thus, the persist-
ent active disease present in pregnant AS patients pro-
vides a pro-inflammatory milieu that might overrule the
regulatory features of γδT cells.
The limitations of our study are the limited and un-
equal number of patients and controls, and the scarce
pre-pregnancy and first trimester data of healthy preg-
nant women. Differences in the frequency and function
of γδT cells might be missed in early pregnancy of
healthy controls. However, we assume that age-matched,
non-pregnant healthy women would not differ from
healthy women examined prior to conception.
Conclusions
In conclusion, here we observed functional changes of
γδT cells that are associated with disease activity in a co-
hort of pregnant versus non-pregnant RA patients. These
functional changes of γδT cells in pregnant RA patients
which were mainly reflected by decreases of TNFα- and
IFNγ-positive γδT cells seem to be a consequence of an
anti-inflammatory environment. No such changes of γδT
cells were seen in AS, a disease that remains active during
pregnancy. The more tolerogenic profile of γδT cells in
pregnant RA patients might contribute to the process of
immunomodulation in pregnancy.
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Additional file 1: Figure S1. Longitudinal changes of TNFα-producing
γδT cells in pregnant RA patients. Patients with rheumatoid arthritis were
analyzed for the percentages (A) and the mean fluorescence intensities
(MFI) (B) of TNFα-producing CD3 cells (left panel), Vδ1 cells (middle
panel) and Vδ2 cells (right panel) before pregnancy (pre), at each trimes-
ter (1T, 2T, 3T) and postpartum (pp). Values are expressed as median and
interquartile ranges. *P < 0.05. (PDF 33 kb)
Additional file 2: Figure S2. Reduced pro-inflammatory cytokine profile
of γδT cells in pregnant versus non-pregnant RA patients. Peripheral
blood mononuclear cells from healthy women (HC), patients with
rheumatoid arthritis (RA), and patients with ankylosing spondylitis (AS)
were stained for intracellular cytokines. Mean fluorescence intensity (MFI)
of TNFα (A), IFNγ (B), IL-17 (C) and IL-10 (D) among CD3 cells (left panels),
Vδ1 cells (middle panels) and Vδ2 cells (right panels) from non-pregnant
(np, white boxes) and pregnant women (third trimester, 3T, grey boxes)
were analyzed. Box plots show the median and the interquartile ranges.
*P < 0.05, **P < 0.01, ***P < 0.001. (PDF 55 kb)
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